Background: After just 42 days, Moderna produced a batch of vaccines ready for clinical trials- from sequence identification through vaccine design, manufacturing, and shipment.
Co-hosted by MIT’s Laboratory for Financial Engineering and Golub Center for Finance and Policy, join a conversation with Stéphane Bancel, CEO of Moderna, as he describes the science, business, and policy issues surrounding the first and currently only company with a vaccine for coronavirus in clinical trials at the National Institute of Health (NIH).
The project is also funded by The Coalition for Epidemic Preparedness Innovations (CEPI), headquartered in Oslo.
IBA is offering a course in “One health approach to bacterial zoonoses of public health interest” on 21-23 October 2019, at the Faculty of Veterinary Medicine, NMBU – Campus Adamstuen in Oslo. The course will feature lectures on the most common bacterial zoonoses in Norway and state-of-the-art methods used in surveillance and research. There will also be opportunity to present your research in poster format as well as networking through dinners and activities in the evening
IBA will cover the course expenses as well as travel and accommodation for members that are PhD students, medical “forskerlinje” students and postdocs (please review our funding guidelines here). For other members we cover the course fee only.
For more details including the program see the course page.